Gentiva Health (UNKNOWN:GTIV.DL) shareholders got some welcome news yesterday, as shares gained 62% in the wake of Kindred Health's (NYSE:KND) announcement that it was taking its bid to acquire the company hostile.
So, good news on the price side, and the deal obviously makes sense from Kindred's perspective. But what about Gentiva's? Should shareholders support this deal for the opportunity to diversify away from government payers? Or should they support management, which claims that its "strategy as a stand-alone company will generate substantially more value to our shareholders"?
In this video, from Thursday's Market Checkup, the Motley Fool's health care focused show, health care analysts Michael Douglass and David Williamson consider the potential benefits to Gentiva and whether this is a good deal for shareholders.